https://mirror.vjregenmed.com The Video Journal of Regenerative Medicine Thu, 26 Aug 2021 17:40:28 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.2 https://d2xz56kaqxj8if.cloudfront.net/wp-content/uploads/2023/09/12102509/VJR-Favicon.png https://mirror.vjregenmed.com 32 32 https://mirror.vjregenmed.com/video/eweavu_rpeo-car-t-in-dlbcl-4-year-follow-up-data-from-zuma-1/ Fri, 26 Feb 2021 14:08:28 +0000 http://13.40.107.223/video/eweavu_rpeo-car-t-in-dlbcl-4-year-follow-up-data-from-zuma-1/ Anna Sureda, MD, PhD, Catalan Institute of Oncology, Barcelona, Spain, discusses the four-year follow-up data from the pivotal ZUMA-1 trial of axicabtagene ciloleucel (axi-cel) in adult patients with refractory diffuse large B-cell lymphoma (DLBCL). The four-year overall survival rate among patients after a single infusion of axi-cel was 44%. These are very encouraging results considering the heavily pre-treated patient population included in the pivotal clinical trial. Furthermore, there were no additional toxicity signs reported in this long-term follow-up analysis. This interview took place during the 3rd European CAR T-cell Meeting.

]]> https://mirror.vjregenmed.com/video/qithm86djva-car-t-cells-in-adult-all/ Fri, 26 Feb 2021 14:08:28 +0000 http://13.40.107.223/video/qithm86djva-car-t-cells-in-adult-all/ CD19-directed CAR T-cells have been approved for use in children and young adults up to the age of 25 years with acute lymphoblastic leukemia (ALL). Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, outlines the use of CAR T-cells in adult ALL. Several prognostic factors for CAR-T therapy’s success have been identified, including platelet count before CAR-T infusion, lactate dehydrogenase (LDH) level, and mutated p53. Additionally, Prof. Nagler discusses if CAR T-cells are the definitive therapy for ALL or a pathway to allogeneic transplant. Finally, Prof. Nagler shares new approaches for CAR T-cells in ALL, including CD22-directed CAR T-cells, sequential administration of CD19 and CD22 CAR T-cells, bispecific CARs, and allogeneic CAR T-cells. This interview took place during the 3rd European CAR T-cell Meeting.

]]> https://mirror.vjregenmed.com/video/ncazsqhyl5u-myeloma-patients-europe-collaborating-on-projects-to-benefit-the-myeloma-community/ Fri, 26 Feb 2021 14:08:28 +0000 http://13.40.107.223/video/ncazsqhyl5u-myeloma-patients-europe-collaborating-on-projects-to-benefit-the-myeloma-community/ The Horizon 2020 CARAMBA project consortium investigates SLAMF7-CAR T-cells prepared by Sleeping Beauty gene-transfer for immunotherapy of multiple myeloma. Ananda Plate, LL.B, MSc, Myeloma Patients Europe, Brussels, Belgium, discusses the role of Myeloma Patients Europe (MPE) in the CARAMBA project, which includes capturing patients’ needs, values, and experiences. Ms Plate outlines another project within the European Commission’s Horizon 2020 program that MPE are involved in – the MMPredict. Additionally, MPE participates in public-private partnerships such as the Innovative Medicines Initiative (IMI). This interview took place during the 3rd European CAR T-cell Meeting.

]]> https://mirror.vjregenmed.com/video/jv8jj4d9v4e-management-of-car-t-related-side-effects/ Fri, 26 Feb 2021 14:08:27 +0000 http://13.40.107.223/video/jv8jj4d9v4e-management-of-car-t-related-side-effects/ Ibrahim Yakoub-Agha, MD, PhD, Lille University Hospital, Lille, France, briefly discusses the management of CAR-T related side effects, including cytokine-release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Close monitoring for CRS and ICANS is required throughout the treatment course. Additionally, pre-existing neurological comorbidities may be a risk factor for the development of ICANS. Therefore, the patients should be evaluated before CAR-T therapy to rule out pre-existing neurological abnormalities. This interview took place during the 3rd European CAR T-cell Meeting.

]]> https://mirror.vjregenmed.com/video/sisc-m4mu3q-novel-strategies-to-optimize-car-t-cell-therapy/ Fri, 26 Feb 2021 14:08:27 +0000 http://13.40.107.223/video/sisc-m4mu3q-novel-strategies-to-optimize-car-t-cell-therapy/ Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, discusses approaches to optimize CAR T-cell therapy. CAR T-cell therapies have achieved impressive outcomes in hematological malignancies. However, setbacks such as limited CAR T-cell persistence after infusion, high relapse rates, resistance, and toxicities continue to be experienced. Prof. Nagler outlines novel strategies to improve CAR T-cell function, including novel constructs, new targets, bispecific CAR-T cells, and allogeneic CAR-Ts. This interview took place during the 3rd European CAR T-cell Meeting.

]]> https://mirror.vjregenmed.com/video/p1wgeuidlyw-car-t-cells-in-myeloma-patients-perspective/ Fri, 26 Feb 2021 14:08:27 +0000 http://13.40.107.223/video/p1wgeuidlyw-car-t-cells-in-myeloma-patients-perspective/ CAR T-cell therapy has emerged as a promising therapy for relapsed and/or refractory patients with multiple myeloma. Ananda Plate, LL.B, MSc, Myeloma Patients Europe, Brussels, Belgium, discusses the challenges associated with this therapy from a patients’ perspective. The time lag between the collection and manufacturing of CAR T-cells remains difficult for patients with progressive disease. Side-effects, access to CAR T-cells, and management of expectations are some of the other hurdles related to CAR T-cell therapy. This interview took place during the 3rd European CAR T-cell Meeting.

]]> https://mirror.vjregenmed.com/video/munyqx4p0zc-highlights-from-the-3rd-european-car-t-cell-meeting/ Fri, 26 Feb 2021 14:08:27 +0000 http://13.40.107.223/video/munyqx4p0zc-highlights-from-the-3rd-european-car-t-cell-meeting/ Anna Sureda, MD, PhD, Catalan Institute of Oncology, Barcelona, Spain, shares her highlights from the 3rd European CAR T-cell meeting. Dr Sureda found particularly interesting the sessions on CAR T-cell-related toxicities, patient-reported outcomes, and academic production of CAR T-cell products. In addition, Dr Sureda outlines the importance and value of the EBMT/EHA CAR T-cell meeting, which is the ideal environment to hear the latest updates in CAR T-cell therapy in Europe, but it also provides a global perspective. This interview took place during the 3rd European CAR T-cell Meeting.

]]> https://mirror.vjregenmed.com/video/4ytxyslsqzu-the-importance-of-partnering-with-patient-organizations/ Fri, 26 Feb 2021 14:08:27 +0000 http://13.40.107.223/video/4ytxyslsqzu-the-importance-of-partnering-with-patient-organizations/ Ananda Plate, LL.B, MSc, Myeloma Patients Europe, Brussels, Belgium, outlines the importance of partnering with patient organizations in research projects, focusing on Horizon 2020 projects such as CARAMBA. Patient organizations provide relevant patient and caregiver input to projects. In CARAMBA, Myeloma Patients Europe plays an important role in capturing and evaluating what patients and carers value, the patients’ experience while undergoing CAR-T therapy as well as patients’ expectations. This interview took place during the 3rd European CAR T-cell Meeting.

]]> https://mirror.vjregenmed.com/video/ursnkl2riek-nk-car-immunotherapy-where-are-we-now/ Fri, 26 Feb 2021 14:08:27 +0000 http://13.40.107.223/video/ursnkl2riek-nk-car-immunotherapy-where-are-we-now/ Natural killer (NK) cells are an essential component of the innate immune system and can provide a valuable source of allogeneic adoptive therapy. Concetta Quintarelli, PhD, Bambino Gesù Children Hospital, IRCCS, Rome, Italy, discusses the generation of allogeneic CAR products, in particular CAR NK-cells. Prof. Quintarelli reveals that using bioreactors, her group has generated up to 300 doses of CAR NK-cells. Although the transition from autologous to allogeneic products is challenging, especially the manufacturing process, the group is now generating the NK-cell banks for both hematological malignancies and solid tumors. This interview took place during the 3rd European CAR T-cell Meeting.

]]> https://mirror.vjregenmed.com/video/vamvbx6x2bq-the-journey-of-car-t-therapy-from-hematological-malignancies-to-solid-tumors/ Fri, 26 Feb 2021 14:08:27 +0000 http://13.40.107.223/video/vamvbx6x2bq-the-journey-of-car-t-therapy-from-hematological-malignancies-to-solid-tumors/ Concetta Quintarelli, PhD, Bambino Gesù Children Hospital, IRCCS, Rome, Italy, discusses the journey of CAR-T therapy from hematological malignancies to solid tumor treatment in the pediatric setting. Patients with solid tumors, in particular high-risk relapsed/refractory neuroblastoma, are being enrolled in a CAR-T program. Results from the trial show a significant improvement in the outcomes of patients. Prof. Quintarelli highlights the need to optimize the CAR-T construct and the manufacturing process to generate CAR T-cells able to penetrate the solid mass and overcome the inhibitory microenvironment. This interview took place during the 3rd European CAR T-cell Meeting.

]]>